Bruker Management
Management criteria checks 4/4
Bruker's CEO is Frank Laukien, appointed in Feb 1991, has a tenure of 33.17 years. total yearly compensation is $5.06M, comprised of 17.3% salary and 82.7% bonuses, including company stock and options. directly owns 29.22% of the company’s shares, worth $3.63B. The average tenure of the management team and the board of directors is 11.3 years and 8.5 years respectively.
Key information
Frank Laukien
Chief executive officer
US$5.1m
Total compensation
CEO salary percentage | 17.3% |
CEO tenure | 33.2yrs |
CEO ownership | 29.2% |
Management average tenure | 11.3yrs |
Board average tenure | 8.5yrs |
Recent management updates
Recent updates
Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Jan 22There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price
Jan 08Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?
Dec 26Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?
Nov 06Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Oct 23Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors
Sep 25Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?
Aug 09Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 27Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet
Jul 11If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity
Jun 26Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Apr 25These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Reasonably Well
Apr 07Bruker (NASDAQ:BRKR) Ticks All The Boxes When It Comes To Earnings Growth
Feb 20Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching
Jan 17Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Dec 30Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now?
Oct 16Here's Why We Think Bruker (NASDAQ:BRKR) Is Well Worth Watching
Oct 03Estimating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)
Sep 19Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Sep 05Bruker Corporation: Upside Is Limited From Here
Aug 24Bruker declares $0.05 dividend
Aug 12CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | US$427m |
Sep 30 2023 | n/a | n/a | US$319m |
Jun 30 2023 | n/a | n/a | US$319m |
Mar 31 2023 | n/a | n/a | US$312m |
Dec 31 2022 | US$5m | US$873k | US$297m |
Sep 30 2022 | n/a | n/a | US$275m |
Jun 30 2022 | n/a | n/a | US$274m |
Mar 31 2022 | n/a | n/a | US$282m |
Dec 31 2021 | US$6m | US$812k | US$277m |
Sep 30 2021 | n/a | n/a | US$270m |
Jun 30 2021 | n/a | n/a | US$238m |
Mar 31 2021 | n/a | n/a | US$204m |
Dec 31 2020 | US$4m | US$689k | US$158m |
Sep 30 2020 | n/a | n/a | US$158m |
Jun 30 2020 | n/a | n/a | US$165m |
Mar 31 2020 | n/a | n/a | US$177m |
Dec 31 2019 | US$5m | US$753k | US$197m |
Sep 30 2019 | n/a | n/a | US$207m |
Jun 30 2019 | n/a | n/a | US$189m |
Mar 31 2019 | n/a | n/a | US$184m |
Dec 31 2018 | US$4m | US$731k | US$180m |
Sep 30 2018 | n/a | n/a | US$98m |
Jun 30 2018 | n/a | n/a | US$92m |
Mar 31 2018 | n/a | n/a | US$84m |
Dec 31 2017 | US$5m | US$704k | US$79m |
Compensation vs Market: Frank's total compensation ($USD5.06M) is below average for companies of similar size in the US market ($USD12.82M).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
CEO
Frank Laukien (63 yo)
33.2yrs
Tenure
US$5,057,195
Compensation
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 33.2yrs | US$5.06m | 29.22% $ 3.6b | |
Executive VP & CFO | 6.1yrs | US$1.90m | 0.031% $ 3.8m | |
Corporate Executive VP and President of Bruker Nano Group & Corporate | 8.8yrs | US$2.50m | 0.051% $ 6.3m | |
President of Bruker CALID Group & Bruker Daltonics Division | 11.3yrs | US$1.28m | 0.083% $ 10.4m | |
President of Bruker BioSpin Group | 5.9yrs | US$1.15m | 0.016% $ 2.0m | |
Senior Director of Investor Relations & Corporate Development | no data | no data | no data | |
General Counsel & Secretary | no data | no data | no data | |
Treasurer & Director of Investor Relations | 16.1yrs | no data | no data | |
President and CEO of Bruker Energy & Supercon Technologies | 16yrs | US$967.91k | 0.0081% $ 1.0m |
11.3yrs
Average Tenure
61yo
Average Age
Experienced Management: BRKR's management team is seasoned and experienced (11.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 33.2yrs | US$5.06m | 29.22% $ 3.6b | |
Independent Director | 8.7yrs | US$241.01k | 0.015% $ 1.9m | |
Independent Director | 8.4yrs | US$224.01k | 0.015% $ 1.9m | |
Independent Director | 16.9yrs | US$229.01k | 0.052% $ 6.5m | |
Independent Lead Director | 24.2yrs | US$231.01k | 0.024% $ 3.0m | |
Independent Director | 6.9yrs | US$224.01k | 0.014% $ 1.7m | |
Independent Director | 8.7yrs | US$219.01k | 0.015% $ 1.9m | |
Independent Director | 3.6yrs | US$214.01k | 0.0056% $ 690.7k | |
Independent Director | 7.9yrs | US$214.01k | 0.0084% $ 1.0m | |
Independent Director | 2yrs | US$154.52k | 0.0026% $ 323.0k |
8.5yrs
Average Tenure
65yo
Average Age
Experienced Board: BRKR's board of directors are considered experienced (8.5 years average tenure).